The prognostic effect on childhood acute lymphoblastic leukemia of CD34+CD38− expressed in leukemia cells

Abstract

Objective Acute lymphoblastic leukemia is the most common malignant disease in children. CD34 and CD38 are expressed in both normal and leukemia cells, but studies of their prognostic associations in childhood acute lymphoblastic leukemia are limited. The aim of this study was to investigate the prognostic effect of CD34 + CD38− leukemia cells in this childhood cancer.Methods From January 2014 to January 2019, children with newly diagnosed acute lymphoblastic leukemia were included in this study and followed up until July 2020. The participants were divided into CD34+ and CD34− groups according to CD34 expression level at diagnosis, and the CD34+ group was further divided into CD34 + CD38− and CD34 + CD38+ subgroups based on CD38 expression level. We tracked clinical biological features, therapeutic outcomes, and other patient data for comparisons.Results The OS and EFS did not differ significantly between the CD34+ and CD34− groups (both P > 0.05). CD34+CD38- group and CD34+CD38+ group were further compared. OS differed significantly between these two groups (χ2 = 3.89, P = 0.048), as did the recurrence rate (χ2 = 5.04, P = 0.025), but EFS did not (χ2 = 1.45, P > 0.05). Survival analysis in patients with recurrence showed a significantly higher OS for the CD34 + CD38+ group compared with the CD34 + CD38− group (χ2 = 5.08, P = 0.024). The CD34+CD38- group and CD34+CD38+ group were matched for propensity scores. When recurrence was compared in the two groups after matching, the difference was statistically significant (P < 0.001).Conclusion CD34+ and CD34− expression does not differ by prognosis in children with acute lymphoblastic leukemia, but CD34 + CD38− may indicate a poor prognosis.

Keywords

• Acute lymphoblastic leukemia (ALL)
• CD34
• CD38
• prognosis
• recurrence
• Leukemic stem cells (LSCs)‌